April 17th Options Now Available For UiPath (PATH)

UiPath (PATH) option strategies: selling the $13 put (bid $1.43) obligates purchase at $13 with an effective cost basis of $11.57 vs. the $13.23 spot price; the $13 strike is ~2% OTM, has a 60% probability of expiring worthless and implies an 11.00% return (60.87% annualized) to expiration. A covered-call using the $14 call (bid $1.38) on shares bought at $13.23 would cap upside at $14 (~6% premium) and deliver a 16.25% total return if called by the April 17 expiry; the $14 strike has a 49% chance to expire worthless and a 10.43% YieldBoost (57.72% annualized). Implied volatilities are high (put 84%, call 80%) versus trailing 12-month volatility of 61%.

Analysis

Market structure: The immediate winners are yield-seeking option sellers and market-makers collecting rich premium (PATH Apr17 $13 put bid $1.43; $14 call bid $1.38) while directional call buyers and pure long holders risk leaving upside on the table. Implied vol (80–84%) sits ~20–25 pts above trailing realized (61%), signaling supply of optionality is valued high — if selling flows increase, expect IV compression and a dampening of intraday gamma-driven moves. Cross-asset impact is limited; however heavy put-selling could transiently bid shares (and depress cheap hedging demand), mildly compressing equity implied vol vs fixed income and FX which should remain uncoupled absent macro shock.

Risk assessment: Tail risks include an earnings-guidance miss, customer churn in the RPA/automation market, or a sector-wide macro tech drawdown that would spike IV >+50 pts and produce >30% downside in weeks. Immediate horizon (days–to–Apr17) is dominated by option expiry probabilities (put worthless ~60%, call worthless ~49%); short-term (1–3 months) depends on IV mean reversion and quarterly results; long-term (quarters–years) reverts to fundamentals — ARR growth, churn, margin leverage. Hidden dependencies: broker assignment mechanics, concentrated assignment forcing emergency sales, and margin financing costs that can magnify losses; catalysts are PATH earnings, large customer announcements, and macro CPI/jobs prints.

Trade implications: Active, capital-efficient plays: (1) sell cash‑secured PATH Apr17 $13 puts size 0.5–2.0% portfolio to capture ~11% premium (cost basis $11.57) — set close/roll if PATH < $11.50 or IV rises +10 pts; (2) buy PATH up to $13.23 and sell Apr17 $14 covered calls to target 16.25% to expiry, roll out/ up if >$14; (3) volatility play: sell a small Vega position (30–45 day strangle or short ATM call) only if willing to delta-hedge intraday and cap loss at 2–3% portfolio. Rotate marginal exposure away from high-multiple AI software peers into names with >20% free-cash-flow margins.

Contrarian angles: Consensus underweights the probability that IV overstates fundamental risk — if PATH reports benign earnings, IV compression could produce >10–20% short-term upside unrecognized by buy-and-holders. Conversely, selling premium is not free: past analogs (post-IPO tech IV compressions) produced steady yield until a single event triggered >40% gap moves; therefore treat option-selling as a tactical yield strategy, not core conviction. Unintended consequence: aggressive put assignment can force concentrated long position and financing strain; size accordingly.

Key Decisions for Investors

• Sell cash-secured PATH Apr17 $13 puts (bid ~1.43) sized 0.5–2.0% of portfolio to achieve an effective cost basis of $11.57; close or roll if PATH < $11.50 or implied vol increases by >10 implied-volatility points.
• Establish a covered-call position: buy PATH up to $13.23 and sell Apr17 $14 calls to pocket ~16.25% total return if called; if PATH > $14 before expiry, roll out 30–60 days or take profit and redeploy proceeds into lower-IV software names.
• If you have a volatility edge, sell a small, hedged 30–45 day strangle on PATH (net short Vega) sized to 0.5–1.0% portfolio and maintain intraday delta-hedging; cap maximum drawdown at 2–3% portfolio and liquidate on IV spike >+20 pts.
• Avoid large outright long positions in high-multiple RPA/software peers; shift 2–4% of equity sleeve into cash-flow positive enterprise software with >20% FCF margin until post-earnings volatility normalizes.
• Monitor three triggers over next 30 days before enlarging positions: PATH quarterly EPS/ARR release, IV movement +/-10 pts from current (~80–84%), and PATH price breaching $11.50 (stop/close threshold for option sellers).